SMC vetoes Sanofi's Jevtana, AZ's Vimovo and Merck's Emend, but OKs Simponi again
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium yesterday announced that it was unimpressed with Sanofi-Aventis' Taxotere follow on Jevtana (cabazitaxel) for metastatic prostate cancer. However, it said yes to Merck & Co's Simponi (golimumab) for rheumatoid arthritis and Novartis' Lucentis (ranibizumab) for CRVO.